Friday, 10 April 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 10 April 2026
News

$210K tit-for-tat Aussie Code fines

 Posted 9 April 2026 AM

The battle for the local obesity market is heating up with a Medicines Australia Code of Conduct complaint by Novo Nordisk resulting in a $130,000 fine for Eli Lilly, which counter-claimed resulting in an $80,000 fine for Novo Nordisk.

After successful intercompany dialogue, an initial, much broader complaint by Novo was whittled down to a dispute over one promotional item - a Leave Behind by Lilly relating to the SURMOUNT-5 head-to-head trial between Mounjaro and Wegovy for weight loss.

To see the whole article, please login

Popular

Trump tariffs unleash hidden chaos
What Chat says about your drugs
Four brands hit with price cuts
Marketers 'not quite up to notch'
Latest Jobs
Pharma in Focus  Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home